Supercede Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $4M

Overview

Supercede Therapeutics is a private, preclinical-stage biotech applying an AI/ML-enhanced platform to discover and develop small molecule drugs. Its lead asset, STX-001, is a novel oral ACTRII inhibitor in preclinical development for obesity, aiming to uniquely reduce fat while increasing lean muscle mass. The company is led by founder and CEO Ilan Zipkin, Ph.D., a seasoned biotech investor and entrepreneur, and appears to be in a formative, pre-revenue stage building its initial pipeline and team.

MetabolicRenalNeurological

Technology Platform

Integrated bioinformatics (AI/ML) platform applied across drug discovery stages from target identification to lead compound generation.

Funding History

1

Total raised:$4M

Seed$4MUndisclosedJun 15, 2022

Opportunities

The massive and growing obesity market, particularly the need for therapies that counteract muscle loss associated with potent GLP-1 drugs, presents a clear niche.

The company's AI/ML platform, if validated, could allow for rapid, cost-effective pipeline generation across multiple disease areas.

Risk Factors

The company is at a high-risk, preclinical stage with an unproven platform and a lead asset that has not entered human trials.

It faces intense competition in obesity and must successfully build out its team and secure significant funding to advance.

Competitive Landscape

In obesity, Supercede will compete with large pharma (Novo Nordisk, Eli Lilly) and biotechs developing next-generation incretins and combination therapies. Its platform also places it in competition with other AI-driven drug discovery companies (e.g., Recursion, Exscientia, Insilico Medicine) for talent, funding, and partnerships.

More companies in AI / Machine Learning →More companies in United States →